Meeting
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
Authors
Kelvin K H Bao
Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
Kelvin K H Bao , Leone Sutanto , Shirley S W Tse , Ka Man Cheung , Jeffrey C H Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1052)
DOI
10.1200/JCO.2021.39.15_suppl.1052
Abstract #
1052
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim
Poster
2017 ASCO Annual Meeting
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
First Author: Kevin Kalinsky
Poster
2023 ASCO Annual Meeting
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
First Author: Rachel M. Layman